Ocular Therapeutix, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows how the company is doing financially every three months, helping investors track progress.
Updates investors on revenue, costs, and profits for the second quarter of the year.
More shares available for employee rewards; new permanent CFO gets $535,100 salary and stock options.
Shows how the company is doing financially every three months, helping investors track progress.
Updates investors on revenue, costs, and profits for the first quarter of the year.
Shows progress on an important eye disease treatment; positive results could help patients and the company.
Complete yearly financial picture shows total revenue, expenses, and profits for all of 2025.
Stocky reads Ocular Therapeutix, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Ocular Therapeutix, Inc.'s most recent tracked filing was a 10-Q on 3 Aug 2026: Company files quarterly financial report for Q2 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.